Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Masimo CorporationNASDAQ: MASI

Net Margin · Q1 FY2026 · quarter ended Apr 2026

Net margin widens to 14.1%

Net margin was 14.1% in Q1 FY2026, up 60.0 pp from a year earlier. On a trailing-twelve-month basis it was 4.9%, up 32.0 pp year over year. Over 3 fiscal years it narrowed by 17.0 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 2 analysts of 19.6% for the fiscal year ending Jan 2027, up from -9.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
14.1%-2.4 pp QoQ
Last fiscal yearJan 2026
-9.9%+4.6 pp YoY
LTMApr 2026
4.9%+32.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+60.0 pp+5.1 pp-55.0 pp
1 year+4.6 pp+29.6 pp+24.9 pp
3 years-17.0 pp+31.3 pp+48.2 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-9.9%
Year-over-year change
+4.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How MASI compares with its peers on the latest reported figures

  • MASI's LTM Apr 2026 net margin of 4.9% is the 5th highest of the 10 companies compared; the peer median is 3.0%.
  • Its year-over-year change of +32.0 pp is the 2nd highest of 10, against a peer median of -1.6 pp.
  • Over three fiscal years its change of -17.0 pp compares with a peer median of -1.2 pp.
MASI Competitors Peer median
Net Margin for MASI and competitors
Company Period LTM level YoY 3-year change
STVNStevanato Group S.p.A.LTM Jun 202611.0% -0.8 pp-2.7 pp
ATRAptarGroup, Inc.LTM Jun 20269.2% -1.6 pp+3.2 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 20268.6% -3.9 pp+158.9 pp
RGENRepligen CorporationLTM Jun 20265.3% +7.3 pp-16.6 pp
MASIMasimo CorporationLTM Apr 20264.9% +32.0 pp-17.0 pp
HSICHenry Schein, Inc.LTM Jun 20263.0% -0.1 pp-1.2 pp
MOHMolina Healthcare, Inc.LTM Sep 2026-0.1% -2.1 pp-1.4 pp
AVTRAvantor, Inc.LTM Jun 2026-8.8% -19.1 pp-17.2 pp
BAXBaxter International Inc.LTM Jun 2026-9.3% -7.8 pp+15.7 pp
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-69.0% +41.3 pp+662.6 pp
ABVXAbivax S.A.FY2025— ——
Peer median (excluding MASI) 3.0%-1.6 pp-1.2 pp

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Revenue1.24B2.04B2.05B2.09B1.53B
Cost of Revenue430.8M977M1.04B1.09B581.7M
Gross Profit808.4M1.06B1B1B945.2M
Gross Margin65.2%52.0%49.0%48.0%61.9%
Research & Development137.2M191.4M175.2M222.8M126.4M
Selling, General & Admin395.4M657.4M664M743.8M506M
Operating Expenses532.6M848.8M867M1.27B632.4M
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
EBITDA310.3M355.2M236.7M(158.7M)344.6M
EBITDA Margin25.0%17.4%11.6%-7.6%22.6%
Operating Income275.8M210M136.5M(266.7M)312.8M
Operating Margin22.3%10.3%6.7%-12.7%20.5%
Interest Income900K1.8M3M4.8M3.4M
Interest Expense300K25.7M50.3M43.6M33.2M
Other Income / Expenses(1.4M)(16.6M)(48.4M)(38.6M)(40.2M)
Income Before Tax274.4M193.4M88.1M(305.3M)272.6M
Pre-Tax Margin22.1%9.5%4.3%-14.6%17.9%
Income Tax Expense44.8M49.9M6.6M(400K)64.9M
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Net Margin18.5%7.0%4.0%-14.6%-9.9%
EPS (Basic)4.162.681.54(5.72)(2.83)
EPS (Diluted)3.982.601.51(5.72)(2.80)
Weighted Avg Shares55.17M53.6M52.8M53.3M53.6M
Weighted Avg Shares (Diluted)57.68M55.2M54.1M53.3M54.2M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.